Close
Close

Santhera Pharmaceuticals - Duchenne Muscular Dystrophy

Partner

Not provided

Rare Disease

Duchenne Muscular Dystrophy

Sponsor

Santhera Pharmaceuticals

Access Program Information

The primary objective of this Expanded Access Program is to provide idebenone as a treatment for eligible participants with Duchenne Muscular Dystrophy before it is commercially available in the United States (U.S.) for the indication of DMD.

Contact

Contact: John Karafilidis, PharmD (978-427-7102)

Locations
  • United States
  • Phoenix, Arizona, United States
  • United States
  • Iowa City, Iowa, United States
  • United States
  • Baltimore, Maryland, United States

Free Newsletter